NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

McNamara, MG, Swain, J, Craig, Z et al. (11 more authors) (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

Metadata

Authors/Creators:
Dates:
  • Published: 20 May 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Funding Information:
FunderGrant number
Cancer Research UKA25447
Baxalta GmbHNot Known
Depositing User: Symplectic Publications
Date Deposited: 17 Oct 2019 12:10
Last Modified: 29 Jun 2020 13:36
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS4158
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)